Bruce Edward Gerlitz

Title: Bruce Edward Gerlitz: Innovator in Protein C Derivatives

Introduction

Bruce Edward Gerlitz is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of biochemistry, particularly in the development of novel protein C derivatives. With a total of 6 patents to his name, Gerlitz's work has the potential to impact the treatment of various thrombotic disorders.

Latest Patents

Gerlitz's latest patents focus on innovative protein C derivatives. These novel polypeptides retain the biological activity of the wild-type human protein C while exhibiting substantially longer half-lives in human blood. This advancement means that these polypeptides will require either less frequent administration or smaller dosages than the wild-type human protein C in treating vascular occlusive disorders, hypercoagulable states, thrombotic disorders, and disease states predisposed to thrombosis. Additionally, another patent describes human protein C derivatives that have increased anti-coagulation activity and resistance to inactivation by serpins. These derivatives also maintain the biological activity of the wild-type human protein C and will similarly require less frequent administration or smaller dosages in treating acute coronary syndromes and other related conditions.

Career Highlights

Bruce Edward Gerlitz is currently associated with Eli Lilly and Company, where he continues to innovate in the field of biochemistry. His work has garnered attention for its potential to improve patient outcomes in various medical conditions.

Collaborations

Some of his notable coworkers include Brian W Grinnell and Bryan Edward Jones, who have collaborated with Gerlitz on various projects within the company.

Conclusion

Bruce Edward Gerlitz is a prominent inventor whose work on protein C derivatives is paving the way for advancements in medical treatments. His contributions are significant in the ongoing fight against thrombotic disorders and related health issues.